Our commitment to collaboration extends to every aspect of our
oncology work–from research and development to clinical trials, from
product availability to patient education.
Our internal research efforts are balanced with external
collaborations across the highest levels of industry, academia and
government. It is this intense focus on collaboration to bring
together the best and smartest minds in oncology that will help us
Some of our partners include:
AbbVie and Genentech pioneered BCL-2 research with the joint
development of venetoclax. AbbVie and Genentech continue to partner in
investigating venetoclax in chronic lymphocytic leukemia and other
hematologic cancers and conditions.
AbbVie and The University of Texas’ MD Anderson Cancer Center have
joined forces to find new ways to unleash the immune system’s
potential to fight cancer. The three-year collaboration is focused on
creating efficiencies in preclinical and clinical studies to advance
the field of immuno-oncology.
AbbVie and Bristol-Myers Squibb jointly developed elotuzumab. In
addition to the approved indication in multiple myeloma, AbbVie and
BMS have ongoing clinical trials for other assets and types of cancer.
See the additional companies we collaborate with below.